Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock a sizeable new ...

Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease ...

People suffering from the early onset of Alzheimer's disease are being given access to a revolutionary drug that's being hailed as a potential cure. The drug, Xanamem, works by blocking the ...

IGC Pharma, Inc, an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer’s disease and transforming patient care with fast-acting, safe, and ...

Axsome Therapeutics (NASDAQ:AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05, or dextromethorphan-bupropion, in the treatment of agitation in ...

Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681).

By leveraging advanced digital outreach tools, we aim to enhance trial awareness, streamline recruitment, and advance IGC-AD1's development as a transformative therapy for Alzheimer's agitation.

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's ...